[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).",
    "url": "https://finnhub.io/api/news?id=7175f9b5943a38d0306f0a5f41b12261a5475d803bf608fcadf6c19abc5e5651",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747946040,
      "headline": "Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen",
      "id": 134658389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).",
      "url": "https://finnhub.io/api/news?id=7175f9b5943a38d0306f0a5f41b12261a5475d803bf608fcadf6c19abc5e5651"
    }
  },
  {
    "ts": null,
    "headline": "Better Weight Loss Stock: Amgen or Viking Therapeutics?",
    "summary": "Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons.  Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate.  Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance.",
    "url": "https://finnhub.io/api/news?id=b5df438b261d0339b69f61b7d2d3a9c92a877ba3e77f60bebb2c088bea8b5561",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747926300,
      "headline": "Better Weight Loss Stock: Amgen or Viking Therapeutics?",
      "id": 134658679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons.  Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate.  Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance.",
      "url": "https://finnhub.io/api/news?id=b5df438b261d0339b69f61b7d2d3a9c92a877ba3e77f60bebb2c088bea8b5561"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying",
    "summary": "Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.",
    "url": "https://finnhub.io/api/news?id=a64bd02accf30f6b463c0fbfffca2c15550ad821cedc01b51995503c697f1e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747922765,
      "headline": "Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying",
      "id": 134658680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Vigil Neuroscience tripled Thursday after Sanofi agreed to buy it for $470 million plus a CVR tied to its experimental Alzheimer's treatment.",
      "url": "https://finnhub.io/api/news?id=a64bd02accf30f6b463c0fbfffca2c15550ad821cedc01b51995503c697f1e4a"
    }
  },
  {
    "ts": null,
    "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=0e165c84dade742626b28ab3b9f1cabb074fc55e6c4bee81b345bc9c1057bd6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747921209,
      "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 134658681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=0e165c84dade742626b28ab3b9f1cabb074fc55e6c4bee81b345bc9c1057bd6d"
    }
  },
  {
    "ts": null,
    "headline": "HyClone Seeks To Quash Amgen's Subpoena Issued In Amgen/Accord Denosumab BPCIA Litigation",
    "summary": "On May 14, 2025, HyClone Laboratories, LLC filed a Motion to Quash in the U.S. District Court for the District of Utah, seeking to quash Amgen Inc.'s subpoena to HyClone issued in Amgen's denosumab...",
    "url": "https://finnhub.io/api/news?id=3df1999a795394cf8504196cc070bbb424837e61e98730fd36883461c1fc236f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747894448,
      "headline": "HyClone Seeks To Quash Amgen's Subpoena Issued In Amgen/Accord Denosumab BPCIA Litigation",
      "id": 134647049,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "On May 14, 2025, HyClone Laboratories, LLC filed a Motion to Quash in the U.S. District Court for the District of Utah, seeking to quash Amgen Inc.'s subpoena to HyClone issued in Amgen's denosumab...",
      "url": "https://finnhub.io/api/news?id=3df1999a795394cf8504196cc070bbb424837e61e98730fd36883461c1fc236f"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Awarded $407 Million In Amgen Antitrust Suit",
    "summary": "On May 15, 2025, a jury returned a verdict finding Amgen Inc. liable for antitrust violations and awarding Regeneron Pharmaceuticals, Inc. over $400 million in damages. As we reported previously,...",
    "url": "https://finnhub.io/api/news?id=5674b364599abfd6112dd6c74115996988e7253f03327794ca3ef50541f9de7e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747879927,
      "headline": "Regeneron Awarded $407 Million In Amgen Antitrust Suit",
      "id": 134636016,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "On May 15, 2025, a jury returned a verdict finding Amgen Inc. liable for antitrust violations and awarding Regeneron Pharmaceuticals, Inc. over $400 million in damages. As we reported previously,...",
      "url": "https://finnhub.io/api/news?id=5674b364599abfd6112dd6c74115996988e7253f03327794ca3ef50541f9de7e"
    }
  }
]